Riesz T, Riskó Z, Winkler V, Juhász J
Neoplasma. 1976;23(4):409-20.
At present it is obvious that the incidence of second malignancies in patients with malignant diseases increases after prolonged treatment with immunosuppressive, or antineoplastic agents. The occurrence of such additional malignant diseases was analysed in our five-years autopsy material. During this period 7670 autopsies were performed. Malignant diseases were observed in 1707 cases (22.1%) and among them in 58 cases were proved multiple primary malignant neoplasms (3.3%). The average time between the occurrence of initial and second tumors was 29 months. The frequency of second tumors in patients with leukemias (mainly chronic lymphocytic leukemia) were four times higher than in patients with tumors of epithelial origin. Hepatocarcinomas arose in cirrhotic livers and astrocytomas were often followed by new malignancies. In consequence of successfully applied surgical, radiological and combined immunosuppressive, antineoplastic therapy the survival of cancer patients lengthened, so among different side-effects of the used therapy the oncogenesis cannot be left out of account. The danger of subsequent malignant tumors makes it imperative that immunosuppression should only be applied when strictly indicated.
目前很明显,恶性疾病患者在接受免疫抑制或抗肿瘤药物的长期治疗后,第二原发性恶性肿瘤的发病率会增加。我们对五年尸检材料中此类额外恶性疾病的发生情况进行了分析。在此期间共进行了7670例尸检。观察到1707例恶性疾病(22.1%),其中58例被证实为多发性原发性恶性肿瘤(3.3%)。初始肿瘤和第二肿瘤出现的平均时间间隔为29个月。白血病患者(主要是慢性淋巴细胞白血病)中第二肿瘤的发生率比上皮源性肿瘤患者高四倍。肝癌发生于肝硬化肝脏,星形细胞瘤之后常出现新的恶性肿瘤。由于成功应用了手术、放射及联合免疫抑制、抗肿瘤治疗,癌症患者的生存期延长,因此在所使用治疗的不同副作用中,肿瘤发生不能被忽视。后续恶性肿瘤的风险使得必须仅在严格指征下才应用免疫抑制。